title: Four cases of investigational therapy with interleukin-11 against acute myocardial infarction.
abstract: We describe four cases of the patients with ST-elevation myocardial infarction (STEMI) that were treated with interleukin-11 (IL-11), a cardioprotective cytokine. Recombinant human IL-11 (rhIL-11), was intravenously administered to two cases at low dose (6 µg/kg) and to two at high dose (25 µg/kg). The cytokine administration started just after the coronary occlusion was confirmed by coronary angiography (CAG), taking 3 h. Following CAG, percutaneous coronary intervention (PCI) was performed as a standard therapy. No serious adverse drug reactions were observed. All the cases left the hospital without the symptom of heart failure. We discuss the possibility of the clinical use of rhIL-11 as an adjunct therapy to PCI for the STEMI patients.
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Nakagawa
authors.affiliation: Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka, 565-0871, Japan.
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Owada
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan. izumi@msic.med.osaka-cu.ac.jp.|Department of Pharmacology, Osaka City University Medical School, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Osaka, 545-8585, Japan. izumi@msic.med.osaka-cu.ac.jp.
authors.forename: Yasukatsu
authors.initials: Y
authors.lastname: Izumi
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nonin
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugioka
authors.affiliation: Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
authors.forename: Daisaku
authors.initials: D
authors.lastname: Nakatani
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Iwata
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Mizutani
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nishimura
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Asahiro
authors.initials: A
authors.lastname: Ito
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Suwako
authors.initials: S
authors.lastname: Fujita
authors.affiliation: Department of Biostatistics, Hyogo College of Medicine, Nishinomiya, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Daimon
authors.affiliation: Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sawa
authors.affiliation: Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center, Suita, Japan.
authors.forename: Masanori
authors.initials: M
authors.lastname: Asakura
authors.affiliation: Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka, 565-0871, Japan.
authors.forename: Makiko
authors.initials: M
authors.lastname: Maeda
authors.affiliation: Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka, 565-0871, Japan. fujio@phs.osaka-u.ac.jp.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Fujio
authors.affiliation: Department of Cardiovascular Medicine, Osaka City University Medical School, Osaka, Japan.
authors.forename: Minoru
authors.initials: M
authors.lastname: Yoshiyama
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017023:Coronary Angiography; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017370:Interleukin-11 / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D062645:Percutaneous Coronary Intervention; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D020127:Recovery of Function; D000072657:ST Elevation Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D002316:Cardiotonic Agents; D015507:Drugs, Investigational; C508611:IL11 protein, human; D017370:Interleukin-11; D011994:Recombinant Proteins
keywords: Cytokine therapy; Interleukin-11; Postconditioning; Reperfusion injury; Translational research